---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-074763"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:14:00.578962+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST

## Summary
- Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.
- Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.
- PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.
- Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions.

## SEC filing metadata
- accession: 0001104659-24-074763
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/0001104659-24-074763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/tm2417478d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-074763
- JSON: https://secwatch.observer/filing/0001104659-24-074763.json
- Plain text: https://secwatch.observer/filing/0001104659-24-074763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.